Dysport News and Research

RSS

Congress faces one-month deadline on doctor payment fix

The doctor payment fix and several marketplace issues, such as insurance red tape and malpractice cases, continue to loom while health care reform efforts stall.

1 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

Large research gap exists in effectiveness, mechanism and safety of drugs in children

Only a few anti-spasticity medications used for children with cerebral palsy are backed by sufficient research to justify their use, according to a new review of scientific literature headed by a UT Southwestern Medical Center neurologist and conducted by a national panel of interdisciplinary experts nationwide.

27 Jan 2010

Use of botulinum type A toxins may offer cost efficient alternative to serotonin reuptake inhibitors

According to an article in the January 2010 edition of Drugs In Dermatology (abstract available at http://jddonline.com ), the use of botulinum type A toxins such as Botox and Dysport may offer a cost efficient alternative to the use of selective serotonin reuptake inhibitors.

5 Jan 2010

Ipsen announces sales highlights for the first nine months of 2009

Ipsen reported its sales for the third quarter and first nine months of 2009.

29 Oct 2009

Dysport drug for treatment of cervical dystonia launched in the United States

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that Dysport® is now available in the United States for the treatment of cervical dystonia in adults.

29 Oct 2009

Dysport, a new wrinkle fighter, available now in the United States

The story: Dysport(TM), a new wrinkle fighter, is now available in the United States. Dysport(TM) is a Botulinum-A enzyme like Botox Cosmetic. Dysport(TM) is positioned as the new arch-nemesis and first direct competitor of Botox Cosmetic in the United States.

26 Oct 2009

World's first plastic surgery iPhone Application launched

Manhattan-based aesthetic plastic surgeon, Dr. David Shafer, announces The Shafer Plastic Surgery App, the world's first plastic surgery iPhone Application.

14 Oct 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

Lidocaine combined with dermal beauty fillers reduces injection discomfort

Beauty injectable fillers such as Restylane(R), Perlane(R) and Juvederm(R) are popular for their ability to restore years of lost facial volume in moments. But for the more sensitive aesthetic patient, the possibility of experiencing injection discomfort or bruising inhibits them from receiving the dramatic visual improvement that could be theirs.

31 Aug 2009

Ipsen Group announces first-half 2009 financial results

The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group’s results for the first half 2009, published today. The full 2009 half year financial report is available on the Group’s web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.

28 Aug 2009

Dysport, an anti-wrinkle alternative to Botox

The new anti-wrinkle facial filler Dysport, which could be used as an alternative to Botox, noticeably reduced frown lines between the eyes, according to users and independent reviewers in a study involving plastic surgeons at UT Southwestern Medical Center.

3 Aug 2009

FDA issues complete response letter to Ipsen for Dysport BLA

Ipsen has announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin Type A, Dysport.

30 Dec 2008